Par-4 prevents breast cancer recurrence

被引：2

作者：

Hebbar, Nikhil ^{[1
]}

Shrestha-Bhattarai, Tripti ^{[1
]}

Rangnekar, Vivek M. ^{[1
,2
,3
,4
,5
]}

机构：

[1] Univ Kentucky, Grad Ctr Toxicol, Lexington, KY 40536 USA

[2] Univ Kentucky, Dept Radiat Med, Lexington, KY 40536 USA

[3] Univ Kentucky, Dept Microbiol Immunol, Lexington, KY 40536 USA

[4] Univ Kentucky, Dept Mol Genet, Lexington, KY 40536 USA

[5] Univ Kentucky, LP Markey Canc Ctr, Lexington, KY USA

来源：

BREAST CANCER RESEARCH | 2013年 / 15卷 / 05期

基金：

美国国家卫生研究院;

关键词：

DOWN-REGULATION; APOPTOSIS; GENE;

D O I：

10.1186/bcr3562

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Therapy resistance and disease recurrence are two of the most challenging aspects in breast cancer treatment. A recent article in Cancer Cell makes a significant contribution toward a better understanding of this therapeutic problem by establishing downregulation of the tumor suppressor Par-4 as the primary determinant of breast cancer recurrence. This viewpoint brings forth the importance of their findings and its implications on future research and therapy.

引用

页数：2

共 50 条

[31] Binding and phosphorylation of Par-4 by Akt is essential for cancer cell survival
Goswami, A
Burikhanov, R
de Thonel, A
Fujita, N
Goswami, M
Zhao, YM
Eriksson, JE
Tsuruo, T
Rangnekar, VM
MOLECULAR CELL, 2005, 20 (01) : 33 - 44
[32] Cancer-selective apoptotic effects of extracellular and intracellular Par-4
T Shrestha-Bhattarai
V M Rangnekar
Oncogene, 2010, 29 : 3873 - 3880
[33] Cancer resistance in transgenic mice expressing the SAC module of par-4
Zhao, Yanming
Burikhanov, Ravshan
Qiu, Shirley
Lele, Subodh M.
Jennings, C. Darrell
Bondada, Subbarao
Spear, Brett
Rangnekar, Vivek M.
CANCER RESEARCH, 2007, 67 (19) : 9276 - 9285
[34] Par-4: A New Activator of Myosin Phosphatase
Vetterkind, Susanne
Lee, Eunhee
Sundberg, Eric
Poythress, Ransom H.
Tao, Terence C.
Preuss, Ute
Morgan, Kathleen G.
MOLECULAR BIOLOGY OF THE CELL, 2010, 21 (07) : 1214 - 1224
[35] Differential expression levels of Par-4 in melanoma
Lucas, T
Pratscher, B
Krishnan, S
Fink, D
Günsberg, P
Wolschek, M
Wacheck, V
Muster, T
Romirer, I
Wolff, K
Pehamberger, H
Eichler, HG
Rangnekar, VM
Jansen, B
MELANOMA RESEARCH, 2001, 11 (04) : 379 - 383
[36] Par-4: a missing link in affective disorders
不详
NEUROSCIENTIST, 2005, 11 (06): : 527 - 527
[37] Inhibition of PAR-4 Prevents Myocyte Apoptosis but Impairs Cardiac Healing and Function after Myocardial Ischemia
Kolpakov, Mikhail A.
Hooshdaran, Bahman
Rafiq, Khadija
Vlasenko, Liudmila
Seqqat, Rachid
Houser, Steven R.
Kunapuli, Satya P.
Sabri, Abdelkarim
CIRCULATION RESEARCH, 2012, 111 (12) : E384 - E384
[38] Par-4 Keeps the Atypical PKCs at Bay
Moscat, Jorge
Diaz-Meco, Maria T.
CELL CYCLE, 2003, 2 (02) : 71 - 72
[39] Cell Death: A New Par-4 the TRAIL
Hart, Lori S.
El-Deiry, Wafik S.
CELL, 2009, 138 (02) : 220 - 222
[40] Suppression of macrophages- Induced inflammation via targeting RAS and PAR-4 signaling in breast cancer cell lines
Thabet, Nadia A.
El-Guendy, Nadia
Mohamed, Mona M.
Shouman, Samia A.
TOXICOLOGY AND APPLIED PHARMACOLOGY, 2019, 385

← 1 2 3 4 5 →